Accessing innovation in a more challenging environment.

In Europe, drug manufacturers are struggling to reach patients quicker, with the gap between market authorization and patient-access widening.

Research conducted by Deloitte (based on EFPIA data) analyzed the length of time it takes drug products to reach patients after obtaining EU marketing authorization across a range of European countries between 2007-2009 and 2014-2016.

The average number of days it takes to complete post-marketing authorization processes has increased from 233 days (for products covered in the 2007-2009 analysis) to 318 days for those covered from 2014-2016. The largest increase in the number of days it takes complete these activities was seen in Portugal (an increase of 288 days), Ireland (an increase of 251 days), and Austria (an increase of 241 days).